Baron R, Binder A, Wasner G. 2010. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol, 9: 807–819.
Beirith A, Santos RSA and Calixto JB, 2002. Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw. Brain Res, 924.2: 219-228.
Benson HAE 2005. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv; 2 : 23 – 33.
Choi AL, Sun G, Zhang Y, Grandjean P. 2012. Developmental fluoride neurotoxicity: a systematic review and meta-analysis. Environ Health Perspect, 120:1362–1368.
Coderre TJ, 1993. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats. Mol Neurobiol, 7: 229–246.
Cunha TM, Verri WAJ, Schivo IR, Napimoga MH, Parada CA, Poole S, Teixeira MM, Ferreira SH, Cunha FQ. 2008. Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol, 83: 824-832.
Dickenson. 1997. Mechanisms of central hypersensitivity: excitatory amino acid mechanisms and their control, in: A. Dickenson, J.-M. Besson (Eds.), The Pharmacology of Pain, Springer, Berlin, 167–209.
Dogrul A, Ossipov MH, Porreca F. 2009. Differential mediation of descending pain facilitation and inhibition by spinal 5-HT3 and 5-HT7 receptors. Brain Res, 1280: 52-59.
Eddy, NB and Leimbach D. 1953. Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Therap, 107: 385-393.
Gadotti VM, Santos AR, Silva CM, Schmeling LO, Machado C and Liz FH. 2005. Antinociceptive action of the extract and the flavonoid quercitrin isolated from Bauhinia microstachya leaves. J Pharmacol, 57: 1345-1351.
Hudspith MJ. 1997. Glutamate: a role in normal brain function, anaesthesia, analgesia and CNS injury. Br J Anaesth, 78: 731– 747.
International Association for the Study of Pain. Pain, IASP Pain Terminology. 1994. http://www.iasp-pain.org/Taxonomy
Leite GO, Sampaio RS, Leite LHI, Menezes IRA, Costa JGM, Campos AR. 2011. Attenuation of visceral pain in mice by the essential oil from Vanillosmopsis arborea Baker. Rev Dor São Paulo, 12: 46-9.
Leite LHI, Leite GO, Coutinho TS, Sousa SDG, Sampaio RS, Costa JGM, Menezes IRA, Campos AR. 2014. Topical Antinociceptive Effect of Vanillosmopsis arborea Baker on Acute Corneal Pain in Mice. Evid Based Compl Alter Med, Article ID 7086364.
Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med, 330: 613–622.
Petersen KL, Rowbotham MC. 1999. A new human experimental pain model: the heat/capsaicin sensitization model. Neuroreport, 10: 1511–1516.
Rang HP, Dale MM, Ritter JM, Moore PK. 2004. Distúrbios neurodegenerativos. In: Farmacologia. 7.Ed., Rio de Janeiro: Elsevier Editora Ltda, 559-573.
Santos NKA, Campos AR, Costa JGM. 2015. The essential oil from Vanillosmopsis arborea Baker (Asteraceae) presents antinociceptive, anti-inflammatory, and sedative effects. Int J Green Pharm, 9:138-142.
Simone DA, Sorkin LS, Oh U, Chung JM, Owens C. 1991. Neurogenic hyperalgesia: central neural correlates in responses of spinothalamic tract neurons. J Neurophysiol, 66: 228–246.
Teixeira MJ.2004. Mecanismos de ocorrência de dor. Revista de Medicina 83: 69-113.
Westlund KN. 2006. The dorsal horn and hyperalgesia. In: Cervero F, Jensen TS, editors. Handbook of Clinical Neurology 2006, Vol 81 (3rd series): Pain. Amsterdam: Elsevier B.V. 178–186.
Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. 2006. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm, 64:1-8.
WHO Normative Guidelines on Pain Management. World Health Organization, Geneva.http://www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines.pdf.